BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, Mcelvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1 -antitrypsin deficiency. Eur Respir J 2017;50:1700610. [DOI: 10.1183/13993003.00610-2017] [Cited by in Crossref: 123] [Cited by in F6Publishing: 91] [Article Influence: 24.6] [Reference Citation Analysis]
Number Citing Articles
1 Ferrarotti I, Ottaviani S. Laboratory diagnosis of AATD. In: Strnad P, Brantly ML, Bals R, editors. α 1 -Antitrypsin Deficiency. Sheffield: European Respiratory Society; 2019. pp. 39-51. [DOI: 10.1183/2312508x.10032418] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Amati F, Simonetta E, Pilocane T, Gramegna A, Goeminne P, Oriano M, Pascual-Guardia S, Mantero M, Voza A, Santambrogio M, Blasi F, Aliberti S. Diagnosis and Initial Investigation of Bronchiectasis. Semin Respir Crit Care Med 2021;42:513-24. [PMID: 34261176 DOI: 10.1055/s-0041-1730892] [Reference Citation Analysis]
3 Roche N. Systemic Medications in Chronic Obstructive Pulmonary Disease: Use and Outcomes. Thorac Surg Clin 2021;31:97-106. [PMID: 33926676 DOI: 10.1016/j.thorsurg.2021.02.008] [Reference Citation Analysis]
4 de la Rosa Carrillo D, López-Campos JL, Alcázar Navarrete B, Calle Rubio M, Cantón Moreno R, García-Rivero JL, Máiz Carro L, Olveira Fuster C, Martínez-García MÁ; Comité Asesor del Documento., Comité Asesor del Documento de consenso sobre el diagnóstico y tratamiento de la infección bronquial crónica en la enfermedad pulmonar obstructiva crónica. Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. Arch Bronconeumol (Engl Ed) 2020;56:651-64. [PMID: 32540279 DOI: 10.1016/j.arbres.2020.04.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
5 Lopes AP, Mineiro MA, Costa F, Gomes J, Santos C, Antunes C, Maia D, Melo R, Canotilho M, Magalhães E, Vicente I, Valente C, Gonçalves BG, Conde B, Guimarães C, Sousa C, Amado J, Brandão ME, Sucena M, Oliveira MJ, Seixas S, Teixeira V, Telo L. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 2018;24 Suppl 1:1-21. [PMID: 30473034 DOI: 10.1016/j.pulmoe.2018.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
6 Bellemare J, Gaudreault N, Valette K, Belmonte I, Nuñez A, Miravitlles M, Maltais F, Bossé Y. The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém). Chronic Obstr Pulm Dis 2021;8. [PMID: 33150777 DOI: 10.15326/jcopdf.8.1.2020.0168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tumpara S, Martinez-Delgado B, Gomez-Mariano G, Liu B, DeLuca DS, Korenbaum E, Jonigk D, Jugert F, Wurm FM, Wurm MJ, Welte T, Janciauskiene S. The Delivery of α1-Antitrypsin Therapy Through Transepidermal Route: Worthwhile to Explore. Front Pharmacol 2020;11:983. [PMID: 32719598 DOI: 10.3389/fphar.2020.00983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Gaeckle NT, Stephenson L, Reilkoff RA. Alpha-1 Antitrypsin Deficiency and Pregnancy. COPD 2020;17:326-32. [PMID: 32308050 DOI: 10.1080/15412555.2020.1754778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hersh CP, Campbell EJ, Scott LR, Raby BA. Alpha-1 Antitrypsin Deficiency as an Incidental Finding in Clinical Genetic Testing. Am J Respir Crit Care Med 2019;199:246-8. [PMID: 30359090 DOI: 10.1164/rccm.201809-1679LE] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Scarlata S, Santangelo S, Ferrarotti I, Corsico AG, Ottaviani S, Finamore P, Fontana D, Miravitlles M, Incalzi RA. Electrophoretic α 1 -globulin for screening of α 1 -antitrypsin deficient variants. Clinical Chemistry and Laboratory Medicine (CCLM) 2020;58:1837-45. [DOI: 10.1515/cclm-2020-0071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med 2021;21:99. [PMID: 33757485 DOI: 10.1186/s12890-021-01466-x] [Reference Citation Analysis]
12 Menga G, Fernandez Acquier M, Echazarreta AL, Sorroche PB, Lorenzon MV, Fernández ME, Saez MS; grupo de estudio DAAT.AR. Prevalence of Alpha-1 Antitrypsin Deficiency in COPD Patients in Argentina. The DAAT.AR Study. Arch Bronconeumol (Engl Ed) 2020;56:571-7. [PMID: 31889566 DOI: 10.1016/j.arbres.2019.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Barrecheguren M, Miravitlles M. Tratamiento aumentativo para el enfisema por déficit de alfa-1 antitripsina: Pro. Archivos de Bronconeumología 2018;54:363-4. [DOI: 10.1016/j.arbres.2018.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Miravitlles M, Calle M, Molina J, Almagro P, Gómez J, Trigueros JA, Cosío BG, Casanova C, López-campos JL, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J, Soler-cataluña JJ. Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Archivos de Bronconeumología (English Edition) 2021. [DOI: 10.1016/j.arbr.2021.03.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
15 Barrecheguren M, Torres-Duran M, Casas-Maldonado F, Miravitlles M. Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). Arch Bronconeumol (Engl Ed) 2021;57:81-2. [PMID: 32197815 DOI: 10.1016/j.arbres.2020.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
16 Unnewehr M, Schlesinger A, Stieglitz S, Köhler D. Greulich T, Fähndrich S, Clarenbach C et al. Alpha-1-Antitrypsin-Mangel (AATM) – Ein Expertenstatement. Pneumologie 2020; 74: 436-442, doi:10.1055/a-1143-8186. Pneumologie 2021;75:69-71. [PMID: 33461236 DOI: 10.1055/a-1251-6424] [Reference Citation Analysis]
17 Barrecheguren M, Miravitlles M. Treatment with inhaled α1-antitrypsin: a square peg in a round hole? Eur Respir J 2019;54:1901894. [DOI: 10.1183/13993003.01894-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Szalontai K, Gémes N, Furák J, Varga T, Neuperger P, Balog JÁ, Puskás LG, Szebeni GJ. Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer. J Clin Med 2021;10:2889. [PMID: 34209651 DOI: 10.3390/jcm10132889] [Reference Citation Analysis]
19 Vianello A, Guarnieri G, Braccioni F, Molena B, Lococo S, Achille A, Lionello F, Salviati L, Caminati M, Senna G. Correlation between α1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses. J Clin Med 2021;10:4493. [PMID: 34640510 DOI: 10.3390/jcm10194493] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cardoso J, Ferreira AJ, Guimarães M, Oliveira AS, Simão P, Sucena M. Treatable Traits in COPD - A Proposed Approach. Int J Chron Obstruct Pulmon Dis 2021;16:3167-82. [PMID: 34824530 DOI: 10.2147/COPD.S330817] [Reference Citation Analysis]
21 Miravitlles M, Calle M, Molina J, Almagro P, Gómez J, Trigueros JA, Cosío BG, Casanova C, López-campos JL, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J, Soler-cataluña JJ. [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Archivos de Bronconeumología 2022;58:T69-81. [DOI: 10.1016/j.arbres.2021.03.026] [Reference Citation Analysis]
22 Gupta N, Gaudreault N, Thériault S, Li PZ, Henry C, Kirby M, Maltais F, Tan W, Bourbeau J, Bossé Y; Canadian Respiratory Research Network and the CanCOLD study group. Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD. Eur Respir J 2020;56:2000958. [PMID: 32482783 DOI: 10.1183/13993003.00958-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res 2019;5:00171-2018. [PMID: 30863774 DOI: 10.1183/23120541.00171-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
24 van Dijk M, Gan CT, Koster TD, Wijkstra PJ, Slebos DJ, Kerstjens HAM, van der Vaart H, Duiverman ML. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Res 2020;6:00322-2019. [PMID: 32984420 DOI: 10.1183/23120541.00322-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
25 Blanco I, Diego I. α1-antitrypsin PI*SZ genotype: a SERPINA1 deficiency haplotype with uncertain clinical and therapeutic implications. Eur Respir J 2020;55:2000713. [PMID: 32554776 DOI: 10.1183/13993003.00713-2020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs 2019;28:891-902. [PMID: 31550938 DOI: 10.1080/13543784.2019.1672656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
27 Hersh CP. Pharmacogenomics of chronic obstructive pulmonary disease. Expert Rev Respir Med 2019;13:459-70. [PMID: 30925849 DOI: 10.1080/17476348.2019.1601559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
28 Veith M, Klemmer A, Anton I, El Hamss R, Rapun N, Janciauskiene S, Kotke V, Herr C, Bals R, Vogelmeier CF, Greulich T. Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology. Int J Chron Obstruct Pulmon Dis 2019;14:2535-42. [PMID: 31819391 DOI: 10.2147/COPD.S224221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J 2018;52:1800328. [PMID: 30049739 DOI: 10.1183/13993003.00328-2018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
30 Forgrave LM, Wang M, Yang D, Demarco ML. Proteoforms and their expanding role in laboratory medicine. Practical Laboratory Medicine 2022;28:e00260. [DOI: 10.1016/j.plabm.2021.e00260] [Reference Citation Analysis]
31 Sucena M, Gomes J, Guimarães C, Miravitlles M. Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. Pulmonology 2020;26:181-3. [DOI: 10.1016/j.pulmoe.2020.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Franciosi AN, Carroll TP, McElvaney NG. Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians. Lancet Respir Med 2019;7:1059-67. [PMID: 31324540 DOI: 10.1016/S2213-2600(19)30141-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cazzola M, Stolz D, Rogliani P, Matera MG. α1-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev 2020;29:190073. [PMID: 32051168 DOI: 10.1183/16000617.0073-2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
34 Evers G, Schulze AB, Thrull M, Hering JP, Schülke C, Wiewrodt R, Wittkowski H, Schmidt LH, Mohr M. Alpha-1 Antitrypsin Deficiency and Pulmonary Morbidity in Patients with Primary Immunodeficiency Disease: A Single-Center Experience. Can Respir J 2020;2020:4019608. [PMID: 32566054 DOI: 10.1155/2020/4019608] [Reference Citation Analysis]
35 Chapuis Cellier C, Narjoz C, Zerimech F, Odou MF, Joly P, Lombard C, Mornex JF, Balduyck M. [Screening for alpha1-antitrypsin deficiency using dried blood spot: Assessment of the first 20 months]. Rev Mal Respir 2020;37:633-43. [PMID: 32859429 DOI: 10.1016/j.rmr.2020.08.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Rathnayake SNH, Van den Berge M, Faiz A. Genetic profiling for disease stratification in chronic obstructive pulmonary disease and asthma. Curr Opin Pulm Med 2019;25:317-22. [PMID: 30762612 DOI: 10.1097/MCP.0000000000000568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Pons M, Núñez A, Esquinas C, Torres-Durán M, Rodríguez-Hermosa JL, Calle M, Tubio-Pérez R, Belmonte I, Rodríguez-Frías F, Rodríguez E, Genescà J, Miravitlles M, Barrecheguren M. Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. J Clin Med 2021;10:1724. [PMID: 33923569 DOI: 10.3390/jcm10081724] [Reference Citation Analysis]
38 Balderacchi AM, Barzon V, Ottaviani S, Corino A, Zorzetto M, Wencker M, Corsico AG, Ferrarotti I. Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency. Clin Chem Lab Med 2021;59:1384-91. [PMID: 33675199 DOI: 10.1515/cclm-2020-1881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Moyer K, Afshar K. Alpha 1 "Hereditary Emphysema" Experience: A Patient-Physician Perspective. Pulm Ther 2020;6:193-9. [PMID: 32519167 DOI: 10.1007/s41030-020-00119-4] [Reference Citation Analysis]
40 Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F. Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidiscip Respir Med 2018;13:39. [PMID: 30338069 DOI: 10.1186/s40248-018-0153-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
41 Burbaum B, Fromme M, Strnad P. [Alpha-1 antitrypsin deficiency: cause and cofactor for liver disease]. Dtsch Med Wochenschr 2021;146:714-8. [PMID: 34062584 DOI: 10.1055/a-1277-9066] [Reference Citation Analysis]
42 Annunziata A, Ferrarotti I, Coppola A, Lanza M, Imitazione P, Spinelli S, Micco PD, Fiorentino G. Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. J Clin Med 2021;10:1546. [PMID: 33916947 DOI: 10.3390/jcm10081546] [Reference Citation Analysis]
43 Aiello M, Frizzelli A, Pisi R, Fantin A, Ghirardini M, Marchi L, Ferrarotti I, Bertorelli G, Percesepe A, Chetta A. Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients. J Asthma 2020;:1-8. [PMID: 32962473 DOI: 10.1080/02770903.2020.1827421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group. Safety of biweekly α1-antitrypsin treatment in the RAPID programme. Eur Respir J 2018;52:1800897. [PMID: 30237305 DOI: 10.1183/13993003.00897-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Ferrarotti I, Ottaviani S, De Silvestri A, Corsico AG. Update on α1-antitrypsin deficiency. Breathe (Sheff) 2018;14:e17-24. [PMID: 30131830 DOI: 10.1183/20734735.015018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Matamala N, Lara B, Gómez-Mariano G, Martínez S, Vázquez-Domínguez I, Otero-Sobrino Á, Muñoz-Callejas A, Sánchez E, Esquinas C, Bustamante A, Cadenas S, Curi S, Lázaro L, Martínez MT, Rodríguez E, Miravitlles M, Torres-Duran M, Herrero I, Michel FJ, Castillo S, Hernández-Pérez JM, Blanco I, Casas F, Martínez-Delgado B. miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease. Arch Bronconeumol (Engl Ed) 2020:S0300-2896(20)30084-3. [PMID: 32439252 DOI: 10.1016/j.arbres.2020.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Dako F, Zhao H, Mulvenna A, Gupta YS, Simpson S, Kueppers F. Relationship Between α1-Antitrypsin Deficiency and Ascending Aortic Distention. Mayo Clin Proc Innov Qual Outcomes 2021;5:590-5. [PMID: 34195551 DOI: 10.1016/j.mayocpiqo.2021.03.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Dummer J, Dobler CC, Holmes M, Chambers D, Yang IA, Parkin L, Smith S, Wark P, Dev A, Hodge S, Dabscheck E, Gooi J, Samuel S, Knowles S, Holland AE. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020;25:321-35. [PMID: 32030868 DOI: 10.1111/resp.13774] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Zamora MR, Ataya A. Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:20406223211002988. [PMID: 34408830 DOI: 10.1177/20406223211002988] [Reference Citation Analysis]
50 Perciaccante A, Charlier P, Negri C, Coralli A, Appenzeller O, Bianucci R. Lessons from the Past: Some Histories of Alpha-1 Antitrypsin Deficiency Before Its Discovery. COPD 2018;15:1-3. [PMID: 29469675 DOI: 10.1080/15412555.2017.1421151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
51 Carrillo DDLR, López-campos JL, Navarrete BA, Rubio MC, Moreno RC, García-rivero JL, Carro LM, Fuster CO, Martínez-garcía MÁ. Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. Archivos de Bronconeumología (English Edition) 2020;56:651-64. [DOI: 10.1016/j.arbr.2020.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Blanco I, Diego I, Bueno P, Pérez-holanda S, Casas-maldonado F, Miravitlles M. Prevalence of α 1 -antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev 2020;29:200014. [DOI: 10.1183/16000617.0014-2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
53 Aiello M, Fantin A, Longo C, Ferrarotti I, Bertorelli G, Chetta A. Clinical manifestations in patients with PI*MMMalton genotypes. A matter still unsolved in alpha-1 antitrypsin deficiency. Respirol Case Rep 2020;8:e00528. [PMID: 32076552 DOI: 10.1002/rcr2.528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Holm KE, Mannino DM, Choate R, Sandhaus RA. Genotype is associated with smoking and other key health behaviors among individuals with alpha-1 antitrypsin deficiency-associated lung disease. Respir Med 2018;143:48-55. [PMID: 30261992 DOI: 10.1016/j.rmed.2018.08.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
55 Pini L, Peroni M, Zanotti C, Pini A, Bossoni E, Giordani J, Bargagli E, Perger E, Ferrarotti I, Vizzardi E, Tiberio L, Bonardelli S, Tantucci C. Investigating the Link between Alpha-1 Antitrypsin Deficiency and Abdominal Aortic Aneurysms. Ann Vasc Surg 2021:S0890-5096(21)00548-3. [PMID: 34455044 DOI: 10.1016/j.avsg.2021.05.064] [Reference Citation Analysis]
56 Jardim JR, Casas-Maldonado F, Fernandes FLA, Castellano MVCO, Torres-Durán M, Miravitlles M. Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. J Bras Pneumol 2021;47:e20200380. [PMID: 34076174 DOI: 10.36416/1806-3756/e20200380] [Reference Citation Analysis]
57 Carreto L, Morrison M, Donovan J, Finch S, Tan GL, Fardon T, Wilson R, Furrie E, Loebinger M, Chalmers JD. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax 2020;75:592-3. [PMID: 32303623 DOI: 10.1136/thoraxjnl-2019-214195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Attaway A, Majumdar U, Sandhaus RA, Nowacki AS, Stoller JK. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2019;14:2089-101. [PMID: 31564856 DOI: 10.2147/COPD.S208591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
59 Esteves Brandão M, Conde B, Seixas S, Clotilde Silva J, Fernandes A. Pulmonary Emphysema in a Child With Alpha-1 Antitrypsin Deficiency: Evaluation of 2 Years of Intravenous Augmentation Therapy. Arch Bronconeumol (Engl Ed) 2019;55:502-4. [PMID: 30871819 DOI: 10.1016/j.arbres.2019.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Tejwani V, Stoller JK. The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:2040622321995691. [PMID: 34408829 DOI: 10.1177/2040622321995691] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
61 Roohani S, Tacke F. Non-invasive assessment for alpha-1 antitrypsin deficiency-associated liver disease: new insights on steatosis and fibrosis in Pi*ZZ carriers. Transl Gastroenterol Hepatol 2019;4:82. [PMID: 32039287 DOI: 10.21037/tgh.2019.11.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Leung SS, Lee P, Most JE, Sundaram B. Images in COPD: Idiopathic Emphysema in a Never Smoker. Chronic Obstr Pulm Dis 2020;7:130-3. [PMID: 32324984 DOI: 10.15326/jcopdf.7.2.2020.0148] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Esquinas C, Miravitlles M. Are There Differences Between the Available Treatments for Emphysema Associated with Alpha-1 Antitrypsin Deficiency? Arch Bronconeumol (Engl Ed) 2018;54:451-2. [PMID: 29625713 DOI: 10.1016/j.arbres.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
64 Mammen JR, Lee JE. Understanding the genetics of chronic obstructive pulmonary disease, α1-antitrypsin deficiency, and implications for clinical practice. J Am Assoc Nurse Pract 2021;33:576-9. [PMID: 34397750 DOI: 10.1097/JXX.0000000000000627] [Reference Citation Analysis]
65 Ruiz-Duque B, Bañuls L, Reinoso-Arija R, Carrasco-Hernandez L, Caballero-Eraso C, Dasí F, Lopez-Campos JL. Methodologies for the Determination of Blood Alpha1 Antitrypsin Levels: A Systematic Review. J Clin Med 2021;10:5132. [PMID: 34768650 DOI: 10.3390/jcm10215132] [Reference Citation Analysis]
66 Franciosi AN, Ralph J, O'Farrell NJ, Buckley C, Gulmann C, O'Kane M, Carroll TP, McElvaney NG. Alpha-1 antitrypsin deficiency-associated panniculitis. J Am Acad Dermatol 2021:S0190-9622(21)00232-2. [PMID: 33516773 DOI: 10.1016/j.jaad.2021.01.074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
68 Ottaviani S, Barzon V, Buxens A, Gorrini M, Larruskain A, El Hamss R, Balderacchi AM, Corsico AG, Ferrarotti I. Molecular diagnosis of alpha1-antitrypsin deficiency: A new method based on Luminex technology. J Clin Lab Anal 2020;34:e23279. [PMID: 32181528 DOI: 10.1002/jcla.23279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
70 Crossley D, Stockley R, Sapey E. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? Drugs Aging 2019;36:823-40. [PMID: 31179525 DOI: 10.1007/s40266-019-00684-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Barrecheguren M, O'Hara K, Wilkens M, Boyd J, Kolda E, Lara B, Chorostowska-Wynimko J, Ferrarotti I, Chlumský J, Clarenbach C, Greulich T, Miravitlles M, Sucena M. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. [PMID: 33447613 DOI: 10.1183/23120541.00523-2020] [Reference Citation Analysis]
72 McElvaney GN, Sandhaus RA, Miravitlles M, Turino GM, Seersholm N, Wencker M, Stockley RA. Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype. Eur Respir J 2020;55:1902410. [PMID: 32165400 DOI: 10.1183/13993003.02410-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
73 López-Campos JL, Carrasco Hernandez L, Caballero Eraso C. Implications of a Change of Paradigm in Alpha1 Antitrypsin Deficiency Augmentation Therapy: From Biochemical to Clinical Efficacy. J Clin Med 2020;9:E2526. [PMID: 32764414 DOI: 10.3390/jcm9082526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis 2018;13:114. [PMID: 29996870 DOI: 10.1186/s13023-018-0856-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 11.8] [Reference Citation Analysis]
75 Ellis P, Turner A. What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD? Arch Bronconeumol (Engl Ed) 2020;56:72-3. [PMID: 31340890 DOI: 10.1016/j.arbres.2019.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
76 Kueppers F. PredictAAT: Accounting for Inflammation in the Diagnosis of Alpha 1 Antitrypsin Deficiency. COPD 2020;17:619-22. [PMID: 32862719 DOI: 10.1080/15412555.2020.1812055] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Huang YT, Wencker M, Driehuys B. Imaging in alpha-1 antitrypsin deficiency: a window into the disease. Ther Adv Chronic Dis 2021;12_suppl:20406223211024523. [PMID: 34408834 DOI: 10.1177/20406223211024523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Miravitlles M, Nuñez A, Torres-durán M, Casas-maldonado F, Rodríguez-hermosa JL, López-campos JL, Calle M, Rodríguez E, Esquinas C, Barrecheguren M. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17:346-54. [DOI: 10.1080/15412555.2020.1795824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis 2021;12_suppl:20406223211010172. [PMID: 34408831 DOI: 10.1177/20406223211010172] [Reference Citation Analysis]
80 Lechowicz U, Rudzinski S, Jezela-Stanek A, Janciauskiene S, Chorostowska-Wynimko J. Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein. Int J Mol Sci 2020;21:E9187. [PMID: 33276468 DOI: 10.3390/ijms21239187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
81 Deuse T, Tediashvili G, Hu X, Gravina A, Tamenang A, Wang D, Connolly A, Mueller C, Mallavia B, Looney MR, Alawi M, Lanier LL, Schrepfer S. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. Proc Natl Acad Sci U S A 2021;118:e2022091118. [PMID: 34244428 DOI: 10.1073/pnas.2022091118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Balbi B, Sangiorgi C, Gnemmi I, Ferrarotti I, Vallese D, Paracchini E, Delle Donne L, Corda L, Baderna P, Corsico A, Carone M, Brun P, Cappello F, Ricciardolo FL, Ruggeri P, Mumby S, Adcock IM, Caramori G, Di Stefano A. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD. Int J Chron Obstruct Pulmon Dis 2019;14:1879-93. [PMID: 31686800 DOI: 10.2147/COPD.S207203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Veith M, Tüffers J, Peychev E, Klemmer A, Kotke V, Janciauskiene S, Wilhelm S, Bals R, Koczulla AR, Vogelmeier CF, Greulich T. The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis. Int J Chron Obstruct Pulmon Dis 2020;15:2827-36. [PMID: 33192056 DOI: 10.2147/COPD.S271810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Soriano JB, Lucas SJ, Jones R, Miravitlles M, Carter V, Small I, Price D, Mahadeva R; Respiratory Effectiveness Group. Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed. Eur Respir J 2018;52:1800360. [PMID: 29853490 DOI: 10.1183/13993003.00360-2018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
85 Martinez-González C, Blanco I, Diego I, Bueno P, Miravitlles M. Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide. Int J Chron Obstruct Pulmon Dis 2021;16:2617-30. [PMID: 34556982 DOI: 10.2147/COPD.S327803] [Reference Citation Analysis]
86 Belmonte I, Nuñez A, Barrecheguren M, Esquinas C, Pons M, López-Martínez RM, Ruiz G, Blanco-Grau A, Ferrer R, Genescà J, Miravitlles M, Rodríguez-Frías F. Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. Int J Chron Obstruct Pulmon Dis 2020;15:2421-31. [PMID: 33116457 DOI: 10.2147/COPD.S269641] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Miravitlles M, Calle M, Molina J, Almagro P, Gómez JT, Trigueros JA, Cosío BG, Casanova C, López-Campos JL, Riesco JA, Simonet P, Rigau D, Soriano JB, Ancochea J, Soler-Cataluña JJ. Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. Arch Bronconeumol (Engl Ed) 2021:S0300-2896(21)00103-4. [PMID: 33840553 DOI: 10.1016/j.arbres.2021.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
88 Pini L, Paoletti G, Heffler E, Tantucci C, Puggioni F; Asthma and Alpha1-Antitrypsin Research Group. Alpha1-antitrypsin deficiency and asthma. Curr Opin Allergy Clin Immunol 2021;21:46-51. [PMID: 33284159 DOI: 10.1097/ACI.0000000000000711] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Remih K, Amzou S, Strnad P. Alpha1-antitrypsin deficiency: New therapies on the horizon. Curr Opin Pharmacol 2021;59:149-56. [PMID: 34256305 DOI: 10.1016/j.coph.2021.06.001] [Reference Citation Analysis]
90 Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Rodriguez Hermosa JL; EPOCONSUL Study. Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. PLoS One 2018;13:e0198777. [PMID: 29953442 DOI: 10.1371/journal.pone.0198777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
91 Sanduzzi A, Ciasullo E, Capitelli L, Sanduzzi Zamparelli S, Bocchino M. Alpha-1-Antitrypsin Deficiency and Bronchiectasis: A Concomitance or a Real Association? Int J Environ Res Public Health 2020;17:E2294. [PMID: 32235324 DOI: 10.3390/ijerph17072294] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Nakanishi T, Forgetta V, Handa T, Hirai T, Mooser V, Lathrop GM, Cookson WOCM, Richards JB. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur Respir J 2020;56:2001441. [PMID: 32675199 DOI: 10.1183/13993003.01441-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Quinn M, Turner AM, Mahadeva R. Unravelling the risk of (intermediate) antitrypsin deficiency. Thorax 2021;76:214-5. [PMID: 33268455 DOI: 10.1136/thoraxjnl-2020-215693] [Reference Citation Analysis]
94 Manne V, Kowdley KV. Alpha1-Antitrypsin Deficiency: A Cause of Chronic Liver Disease. Clin Liver Dis 2020;24:483-92. [PMID: 32620284 DOI: 10.1016/j.cld.2020.04.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Miravitlles M, Chorostowska-wynimko J, Ferrarotti I, Mcelvaney N, O'hara K, Stolk J, Stockley RA, Turner A, Wilkens M, Greulich T. The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J 2019;53:1900138. [DOI: 10.1183/13993003.00138-2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
96 Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
97 Roche N. Systemic Medications in Chronic Obstructive Pulmonary Disease: Use and Outcomes. Clin Chest Med 2020;41:485-94. [PMID: 32800201 DOI: 10.1016/j.ccm.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
98 Janciauskiene S, DeLuca DS, Barrecheguren M, Welte T, Miravitlles M; Scientific Committee., Participating sites and coordinators. Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. Arch Bronconeumol (Engl Ed) 2020;56:76-83. [PMID: 31153743 DOI: 10.1016/j.arbres.2019.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
99 Quinn M, Ellis P, Pye A, Turner AM. Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives. Ther Clin Risk Manag 2020;16:1243-55. [PMID: 33364772 DOI: 10.2147/TCRM.S234377] [Reference Citation Analysis]
100 Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:20406223211015954. [PMID: 34408833 DOI: 10.1177/20406223211015954] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
101 Craig TJ, Henao MP. Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder. Allergy 2018;73:2110-21. [PMID: 29984428 DOI: 10.1111/all.13558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
102 Rahaghi F, Omert L, Clark V, Sandhaus RA. Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD. J Crit Care 2019;54:212-9. [PMID: 31614323 DOI: 10.1016/j.jcrc.2019.08.027] [Reference Citation Analysis]
103 Alter P, Baker JR, Dauletbaev N, Donnelly LE, Pistenmaa C, Schmeck B, Washko G, Vogelmeier CF. Update in Chronic Obstructive Pulmonary Disease 2019. Am J Respir Crit Care Med 2020;202:348-55. [PMID: 32407642 DOI: 10.1164/rccm.202002-0370UP] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Riley CM, Sciurba FC. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA 2019;321:786-97. [PMID: 30806700 DOI: 10.1001/jama.2019.0131] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
105 Blanco I. A well-designed/conducted study on alpha-1 antitrypsin epidemiology not quoted. Eur Respir J 2018;51:1702662. [DOI: 10.1183/13993003.02662-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Crossley D, Stockley J, Bolton CE, Hopkinson NS, Mahadeva R, Steiner M, Wilkinson T, Hurst JR, Gooptu B, Stockley RA. Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. BMJ Open 2020;10:e036045. [PMID: 32606060 DOI: 10.1136/bmjopen-2019-036045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]